<DOC>
	<DOCNO>NCT01150513</DOCNO>
	<brief_summary>Triple-negative breast cancer ( TNBC ) relatively bad prognosis whereas standard regimen . Some data show platins could improve efficacy advance TNBC . In trial , hypothesis TP ( docetaxel plus carboplatin ) good efficacy EC-T ( epirubicin plus cyclophosphamide follow docetaxel ) .</brief_summary>
	<brief_title>Docetaxel+Carboplatin v Epirubicin+Cyclophosphamide Followed Docetaxel Adjuvant Treatment Triple-negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Triplenegative breast cancer Older 18 year old Have tumor resection surgery Sufficient organ function ( marrow , heart , liver ) Other malignancy Other serious disease ( marrow , heart , liver )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>TRIPLE-NEGATIVE</keyword>
	<keyword>BREAST CANCER</keyword>
</DOC>